Archive · 22 Sep 2025
Pfizer to Buy Metsera, Expanding Obesity Treatment Portfolio
Pfizer, a big drug company, is buying Metsera, another company developing drugs to help people lose weight.
This is part of Pfizer's plan to get into the growing market for obesity treatments, after they stopped working on their own.
Metsera's drugs are still being tested, but Pfizer hopes they will be successful.
The deal involves an initial payment of $4.9 billion with the possibility of paying more.
This market is driven by the demand for weight loss treatment that is currently provided by competitor brands like Wegovy and Zepbound.
Metsera's shareholders still need to approve the deal and regulators will also review it before the deal can be finalized.
Pfizer will acquire Metsera for an initial $4.9 billion.
The deal represents a significant premium for Metsera shareholders.
Metsera has four programs in clinical development.
The acquisition will help Pfizer to expand into obesity treatments.
The deal is expected to close in the fourth quarter of the year.
- Who
- Pfizer is acquiring Metsera.
- What
- Pfizer is entering the obesity drug market.
- When
- The deal was announced recently; expected to close Q4.
- Where
- N/A
- Why
- To enter the obesity treatment market and replace expiring patents.
Pfizer's Perspective
Metsera's Perspective
Strategic Goals
Pfizer's Perspective
Pfizer aims to gain entry into the obesity treatment market to address revenue loss.
Metsera's Perspective
Metsera can advance its development efforts and expand its reach with Pfizer's support.
- Acquirer
- Pfizer Inc.
- Target
- Metsera Inc.
- Deal Value
- $4.9 billion initially, up to $7.3B
- Metsera Share Price Premium
- 42%+
- Metsera Pipeline
- Four programs in clinical development
- Expected Closing
- Q4 of this year
